A Jen­nifer Doud­na-launched up­start nabs $115M for off-the-shelf CAR-Ts

There is no short­age of biotechs pur­su­ing off-the-shelf CAR-Ts, a so-called Holy Grail in on­col­o­gy R&D. Now, less than a month af­ter team­ing up with Ab­b­Vie, a Cal­i­for­nia play­er launched by CRISPR pi­o­neer Jen­nifer Doud­na has re­turned to the ven­ture well, scoop­ing up a big crossover round to help it along.

Cari­bou Bio­sciences took the wraps off a $115 mil­lion Se­ries C on Wednes­day morn­ing, bring­ing their to­tal raise to around $157 mil­lion, CEO Rachel Hau­r­witz said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER